A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab

•In- and outpatient alemtuzumab infusion management in Germany is highly standardized and in accordance with recommendations by the summary of product characteristics.•Infusion-associated reactions (including headache, rash, and pyrexia) present the most common adverse events and are usually mild.•T...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2022-03, Vol.59, p.103670-103670, Article 103670
Hauptverfasser:	Räuber, Saskia, Pawlitzki, Marc, Korsen, Melanie, Kullmann, Jennifer S, Thoene, Daniela, Pfeuffer, Steffen, Rolfes, Leoni, Nelke, Christopher, Melzer, Nico, Ruck, Tobias, Meuth, Sven G
Format:	Artikel
Sprache:	eng
Schlagworte:	alemtuzumab Alemtuzumab - adverse effects Germany Humans infusion management infusion-associated reactions Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - therapy Patient Satisfaction Personal Satisfaction Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!